Simple Summary

Abstract

Haematologica. 2020 Dec 1; 105(12): 2738–2745.
Published online 2020 Oct 9. doi: 10.3324/haematol.2019.242891

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
Ehab Atallah1 and Charles A Schiffer2

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

While the world eagerly awaits an effective vaccine, the current focus is on drug treatments. One such agent, the corticosteroid dexamethasone, has garnered considerable interest due to favourable findings from a recent study out of the UK. Remdesivir and several other agents have also been described as possibly effective treatments. Unfortunately....

In order to harmonize and standardize the management of patients with chronic myeloid leukemia (CML), the European LeukemiaNet (ELN) produced recommendations in the previous years. ELN gathered CML experts to define concepts and formulate the first recommendations for treating CML in 2006 [1]. The remarkable progress in the field of CML mandated updating of these recommendations in 2009 [2], 2013 [3], and recently in 2020 [4].

https://www.tandfonline.com/doi/full/10.1080/17474086.2020.1813564

Authors: Graeme Smith  Jane Apperley  Dragana Milojkovic  Nicholas C. P. Cross  Letizia Foroni  Jenny Byrne Andy Goringe  Anupama Rao  Jamshid Khorashad  Hugues de Lavallade  Adam J. Mead  Wendy Osborne  Chris Plummer  Gail Jones  Mhairi Copland  behalf of British Society for Haematology

Press Release

Key Points

A really interesting paper on the management and incidence of COVID-19 in CML patients in Italy  

https://www.nature.com/articles/s41375-020-0904-z.pdf